Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 3

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Current treatment landscape of acromegaly

Castinetti, Frederic, Ioachimescu, Adriana G·2026·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/clinem/dgag152
Open this paper in CoChat — free account

Abstract

Treatment of acromegaly includes surgery followed by chronic medical therapy for persistent growth hormone (GH) excess, and, in some patients, radiation. Treatment is aimed at biochemical normalization, which improves survival and comorbidities. However, many patients experience lifelong burden related to persistent acromegaly manifestations and adverse treatment effects. Long-acting somatostatin receptor ligand (SRL) therapy with octreotide or lanreotide has been the cornerstone of management. Pasireotide long-acting release, a somatostatin receptor multiligand, achieves more favorable biochemical control rates but is associated with an increased risk of hyperglycemia. Pegvisomant, a GH receptor antagonist, can be used as monotherapy or in combination with SRLs. The spectrum of medical therapy has expanded with the advent of oral octreotide capsules; the oral selective somatostatin receptor subtype 2 agonist, paltusotine; and monthly self-administered subcutaneous octreotide. This review outlines the updates to current acromegaly treatment options and their impact on patient outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/clinem/dgag152

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 131

  1. Melmed, 2025, Consensus on acromegaly therapeutic outcomes: an update, Nat Rev Endocrinol, 21, 718, 10.1038/s41574-025-01148-2 · DOI · Paper page
  2. Baussart, 2025, Outcome of acromegalic patients undergoing endoscopic endonasal surgery: collaborative French and Italian cohort, a 25-year experience, Neurosurg Rev, 48, 654, 10.1007/s10143-025-03797-3 · doi:10.1007/s10143-025-03797-3
  3. Bollerslev, 2019, Management of endocrine disease: individualised management of acromegaly, Eur J Endocrinol, 181, R57, 10.1530/EJE-19-0124 · doi:10.1530/eje-19-0124
  4. Giustina, 2024, Consensus on criteria for acromegaly diagnosis and remission, Pituitary, 27, 7, 10.1007/s11102-023-01360-1 · DOI · Paper page
  5. Kinoshita, 2024, Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests, Pituitary, 28, 4, 10.1007/s11102-024-01487-9 · DOI
  6. Graillon, 2020, Fluctuation analysis of postoperative secretory status in patients operated for acromegaly, Ann Endocrinol (Paris), 81, 11, 10.1016/j.ando.2019.11.002 · doi:10.1016/j.ando.2019.11.002
  7. Starnoni, 2016, Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis, Acta Neurochir (Wien), 158, 2109, 10.1007/s00701-016-2903-4 · DOI
  8. Agrawal, 2020, Prognostic factors of biochemical remission after transsphenoidal surgery for acromegaly: a structured review, Pituitary, 23, 582, 10.1007/s11102-020-01063-x · DOI
  9. Chen, 2017, Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications, Acta Neurochir (Wien), 159, 2193, 10.1007/s00701-017-3318-6 · doi:10.1007/s00701-017-3318-6
  10. Oberman, 2025, Selective resection of the medial wall of the cavernous sinus in pituitary surgery: results of a prospective single center analysis, Pituitary, 28, 19, 10.1007/s11102-024-01476-y · DOI
  11. Calandrelli, 2026, Histopathological and radiological predictors of surgical remission failure in GH-secreting pituitary adenomas, Pituitary, 29, 39, 10.1007/s11102-025-01635-9 · doi:10.1007/s11102-025-01635-9
  12. Almeida, 2018, Reoperation for growth hormone-secreting pituitary adenomas: report on an endonasal endoscopic series with a systematic review and meta-analysis of the literature, J Neurosurg, 129, 404, 10.3171/2017.2.JNS162673 · doi:10.3171/2017.2.jns162673
  13. Anthony, 2015, Significant elevation of growth hormone level impacts surgical outcomes in acromegaly, Endocr Pract, 21, 1001, 10.4158/EP14587.OR · DOI
  14. Coopmans, 2021, Predictors for remission after transsphenoidal surgery in acromegaly: a Dutch multicenter study, J Clin Endocrinol Metab, 106, 1783, 10.1210/clinem/dgab069 · doi:10.1210/clinem/dgab069
  15. Del Corso, 2024, Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis, Pituitary, 27, 537, 10.1007/s11102-024-01432-w · DOI
  16. Konar, 2024, Predictors of remission of acromegaly following surgical treatment in growth hormone-secreting pituitary adenoma, J Neurol Surg B Skull Base, 85, 261, 10.1055/s-0043-57233 · DOI
  17. Cardinal, 2021, Postoperative GH and degree of reduction in IGF-1 predicts postoperative hormonal remission in acromegaly, Front Endocrinol (Lausanne), 12, 743052, 10.3389/fendo.2021.743052 · DOI
  18. Freda, 1998, Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly, J Neurosurg, 89, 353, 10.3171/jns.1998.89.3.0353 · DOI · Paper page
  19. Guo, 2022, Determinants of immediate and long-term remission after initial transsphenoidal surgery for acromegaly and outcome patterns during follow-up: a longitudinal study on 659 patients, J Neurosurg, 137, 618, 10.3171/2021.11.JNS212137 · DOI
  20. Jane, 2011, Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome, J Clin Endocrinol Metab, 96, 2732, 10.1210/jc.2011-0554 · DOI · Paper page
  21. Kraljevic, 2024, Early postoperative growth hormone measurement as a predictive marker for acromegaly remission, J Neuroendocrinol, 36, e13434, 10.1111/jne.13434 · DOI
  22. Krieger, 2003, Assessment of long-term remission of acromegaly following surgery, J Neurosurg, 98, 719, 10.3171/jns.2003.98.4.0719 · DOI
  23. Chong, 2025, Comparison of the clinical and prognostic characteristics of patients with different pathological types in acromegaly, Front Endocrinol (Lausanne), 16, 1571598, 10.3389/fendo.2025.1571598 · DOI
  24. Araujo-Castro, 2024, Differences between GH- and PRL-cosecreting and GH-secreting pituitary adenomas: a series of 604 cases, J Clin Endocrinol Metab, 109, e2178, 10.1210/clinem/dgae126 · DOI
  25. Cremaschi, 2024, Recurrence in acromegaly: two tertiary centers experience and review of the literature, J Endocrinol Invest, 47, 2269, 10.1007/s40618-024-02321-6 · doi:10.1007/s40618-024-02321-6
  26. Colao, 2019, Acromegaly, Nat Rev Dis Primers, 5, 20, 10.1038/s41572-019-0071-6 · DOI · Paper page
  27. Gadelha, 2025, Medical treatment of acromegaly: navigating the present, shaping the future, Endocr Rev, 46, 838, 10.1210/endrev/bnaf020 · doi:10.1210/endrev/bnaf020
  28. Melmed, 2018, A consensus statement on acromegaly therapeutic outcomes, Nat Rev Endocrinol, 14, 552, 10.1038/s41574-018-0058-5 · DOI · Paper page
  29. Colao, 2009, Significant tumour shrinkage after 12 months of lanreotide autogel-120 mg treatment given first-line in acromegaly, Clin Endocrinol (Oxf), 71, 237, 10.1111/j.1365-2265.2008.03503.x · doi:10.1111/j.1365-2265.2008.03503.x
  30. Melmed, 2010, Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension, Pituitary, 13, 18, 10.1007/s11102-009-0191-1 · DOI
  31. Fleseriu, 2023, Treatment patterns, adherence, persistence, and health care resource utilization in acromegaly: a real-world analysis, J Endocr Soc, 7, bvad104, 10.1210/jendso/bvad104 · DOI
  32. Chiloiro, 2024, IGF-I levels during standard lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly, Pituitary, 28, 7, 10.1007/s11102-024-01479-9 · doi:10.1007/s11102-024-01479-9
  33. Fleseriu, 2023, A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly, Pituitary, 26, 9, 10.1007/s11102-022-01285-1 · DOI
  34. Coopmans, 2020, Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly, J Clin Endocrinol Metab, 105, 2964, 10.1210/clinem/dgaa387 · doi:10.1210/clinem/dgaa387
  35. Ilie, 2022, Predictive factors of somatostatin receptor ligand response in acromegaly—a prospective study, J Clin Endocrinol Metab, 107, 2982, 10.1210/clinem/dgac512 · doi:10.1210/clinem/dgac512
  36. Chiloiro, 2024, The multibiomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort, J Clin Endocrinol Metab, 109, 1341, 10.1210/clinem/dgad673 · doi:10.1210/clinem/dgad673
  37. Wildemberg, 2021, Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands, J Clin Endocrinol Metab, 106, 2047, 10.1210/clinem/dgab125 · DOI
  38. Gil, 2022, Data mining analyses for precision medicine in acromegaly: a proof of concept, Sci Rep, 12, 8979, 10.1038/s41598-022-12955-2 · DOI
  39. Lin, 2026, Integrative machine learning approach for predicting resistance to first-generation receptor ligands in acromegaly, J Clin Endocrinol Metab, 111, 484, 10.1210/clinem/dgaf375 · doi:10.1210/clinem/dgaf375
  40. Marques-Pamies, 2024, Personalized medicine in acromegaly: the ACROFAST study, J Clin Endocrinol Metab, 110, 30, 10.1210/clinem/dgae444 · DOI · Paper page
  41. Caron, 2014, Tumor shrinkage with lanreotide autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial, J Clin Endocrinol Metab, 99, 1282, 10.1210/jc.2013-3318 · DOI · Paper page
  42. Benderradji, 2022, Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month, Clin Endocrinol (Oxf), 97, 52, 10.1111/cen.14748 · doi:10.1111/cen.14748
  43. Bevan, 2002, Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size, J Clin Endocrinol Metab, 87, 4554, 10.1210/jc.2001-012012 · DOI · Paper page
  44. Marques, 2019, Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness, Endocr Relat Cancer, 26, 853, 10.1530/ERC-19-0327 · DOI
  45. Chiloiro, 2023, The immune microenviroment in somatotropinomas: from biology to personalized and target therapy, Rev Endocr Metab Disord, 24, 283, 10.1007/s11154-022-09782-1 · DOI
  46. Albarel, 2022, Preoperative medical treatment for patients with acromegaly: yes or no?, J Endocr Soc, 6, bvac114, 10.1210/jendso/bvac114 · doi:10.1210/jendso/bvac114
  47. Yang, 2019, Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and meta-analysis of comparative studies, Sci Rep, 9, 14070, 10.1038/s41598-019-50639-6 · doi:10.1038/s41598-019-50639-6
  48. Ye, 2025, Real-world drug safety study of somatostatin analogs based on the food and drug administration adverse event reporting system database, Eur J Pharmacol, 1005, 178053, 10.1016/j.ejphar.2025.178053 · DOI
  49. Geer, 2020, Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice, BMC Endocr Disord, 20, 117, 10.1186/s12902-020-00595-4 · DOI
  50. Strasburger, 2016, Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly, Eur J Endocrinol, 174, 355, 10.1530/EJE-15-1042 · DOI
  51. Boguszewski, 2023, Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review, Endocrine, 79, 527, 10.1007/s12020-022-03227-0 · DOI
  52. Akirov, 2021, Benefits of a nurse-led home injection service for acromegaly patients treated with somatuline autogel, Endocrine, 71, 453, 10.1007/s12020-020-02529-5 · doi:10.1007/s12020-020-02529-5
  53. Cella, 2021, Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review, Adv Ther, 38, 969, 10.1007/s12325-020-01600-x · doi:10.1007/s12325-020-01600-x
  54. Fleseriu, 2021, Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands, Front Endocrinol (Lausanne), 12, 627711, 10.3389/fendo.2021.627711 · DOI
  55. Remba-Shapiro, 2025, Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection, Eur J Endocrinol, 193, 564, 10.1093/ejendo/lvaf200 · doi:10.1093/ejendo/lvaf200
  56. Brayden, 2021, Transient permeation enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation, Expert Opin Drug Deliv, 18, 1501, 10.1080/17425247.2021.1942838 · DOI
  57. Labadzhyan, 2021, Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results, Pituitary, 24, 943, 10.1007/s11102-021-01163-2 · doi:10.1007/s11102-021-01163-2
  58. Samson, 2020, Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide, J Clin Endocrinol Metab, 105, e3785, 10.1210/clinem/dgaa526 · doi:10.1210/clinem/dgaa526
  59. Samson, 2022, Durable biochemical response and safety with oral octreotide capsules in acromegaly, Eur J Endocrinol, 187, 733, 10.1530/EJE-22-0220 · doi:10.1530/eje-22-0220
  60. Fleseriu, 2022, Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial, Lancet Diabetes Endocrinol, 10, 102, 10.1016/S2213-8587(21)00296-5 · DOI
  61. Fleseriu, 2023, MPOWERED trial open-label extension: long-term efficacy and safety data for oral octreotide capsules in acromegaly, J Clin Endocrinol Metab, 108, 3214, 10.1210/clinem/dgad365 · DOI
  62. Fleseriu, 2024, Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use, Expert Rev Endocrinol Metab, 19, 367, 10.1080/17446651.2024.2363540 · doi:10.1080/17446651.2024.2363540
  63. Ferone, 2025, Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1, J Clin Endocrinol Metab, 110, 1729, 10.1210/clinem/dgae707 · doi:10.1210/clinem/dgae707
  64. Spencer-Segal, 2025, SUN-051 CAM2029, an octreotide subcutaneous depot, provides long-term and sustained biochemical control of acromegaly: final analysis of the core part of the ACROINNOVA 2 phase 3 trial, J Endocr Soc, 9, A863, 10.1210/jendso/bvaf149.1636 · doi:10.1210/jendso/bvaf149.1636
  65. Madan, 2022, Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers, Pituitary, 25, 328, 10.1007/s11102-021-01201-z · doi:10.1007/s11102-021-01201-z
  66. Cristante, 2025, New treatments for acromegaly: is a revolution underway?, Ann Endocrinol (Paris), 86, 101710, 10.1016/j.ando.2025.101710 · doi:10.1016/j.ando.2025.101710
  67. Gadelha, 2024, Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine, J Clin Endocrinol Metab, 110, 228, 10.1210/clinem/dgae385 · doi:10.1210/clinem/dgae385
  68. Biller, 2024, 12535 efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled PATHFNDR-2 study, J Endocr Soc, 8, A625
  69. Castinetti, 2025, Paltusotine: a step toward precision medicine in acromegaly, J Clin Endocrinol Metab, 110, e897, 10.1210/clinem/dgae489 · doi:10.1210/clinem/dgae489
  70. Colao, 2014, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study, J Clin Endocrinol Metab, 99, 791, 10.1210/jc.2013-2480 · DOI · Paper page
  71. Gadelha, 2014, Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial, Lancet Diabetes Endocrinol, 2, 875, 10.1016/S2213-8587(14)70169-X · DOI · Paper page
  72. Colao, 2020, Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study, Eur J Endocrinol, 182, 583, 10.1530/EJE-19-0762 · doi:10.1530/eje-19-0762
  73. Muhammad, 2018, Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study), J Clin Endocrinol Metab, 103, 586, 10.1210/jc.2017-02017 · doi:10.1210/jc.2017-02017
  74. Mondin, 2022, Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis, Front Endocrinol (Lausanne), 13, 935759, 10.3389/fendo.2022.935759 · DOI
  75. Biagetti, 2025, Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis, Rev Endocr Metab Disord, 26, 97, 10.1007/s11154-024-09928-3 · DOI
  76. Pirchio, 2024, Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center, J Endocrinol Invest, 47, 1887, 10.1007/s40618-023-02299-7 · DOI
  77. Coopmans, 2020, T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly, Eur J Endocrinol, 182, 595, 10.1530/EJE-19-0840 · DOI
  78. Gadelha, 2020, Risk factors and management of pasireotide-associated hyperglycemia in acromegaly, Endocr Connect, 9, 1178, 10.1530/EC-20-0361 · DOI
  79. Störmann, 2024, Management of pasireotide-induced hyperglycemia in patients with acromegaly: an experts’ consensus statement, Front Endocrinol (Lausanne), 15, 1348990, 10.3389/fendo.2024.1348990 · DOI
  80. Giustina, 2020, Multidisciplinary management of acromegaly: a consensus, Rev Endocr Metab Disord, 21, 667, 10.1007/s11154-020-09588-z · DOI · Paper page
  81. Fleseriu, 2021, A pituitary society update to acromegaly management guidelines, Pituitary, 24, 1, 10.1007/s11102-020-01091-7 · DOI · Paper page
  82. Brue, 2023, Position statement on the diagnosis and management of acromegaly: the French National Diagnosis and Treatment Protocol (NDTP), Ann Endocrinol (Paris), 84, 697, 10.1016/j.ando.2023.08.003 · DOI
  83. Strasburger, 2018, Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant, Eur J Endocrinol, 178, 321, 10.1530/EJE-17-0996 · doi:10.1530/eje-17-0996
  84. Trainer, 2000, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N Engl J Med, 342, 1171, 10.1056/NEJM200004203421604 · DOI · Paper page
  85. van der Lely, 2001, Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist, Lancet, 358, 1754, 10.1016/S0140-6736(01)06844-1 · DOI · Paper page
  86. Giampietro, 2024, Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis, Endocr Connect, 13, e230247, 10.1530/EC-23-0247 · doi:10.1530/ec-23-0247
  87. Franck, 2017, A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues, Eur J Endocrinol, 176, 421, 10.1530/EJE-16-0956 · doi:10.1530/eje-16-0956
  88. Parkinson, 2007, Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant, J Clin Endocrinol Metab, 92, 190, 10.1210/jc.2006-1412 · DOI
  89. Besser, 2005, Predictors and rates of treatment-resistant tumor growth in acromegaly, Eur J Endocrinol, 153, 187, 10.1530/eje.1.01968 · DOI
  90. Jimenez, 2008, Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials, Eur J Endocrinol, 159, 517, 10.1530/EJE-08-0205 · doi:10.1530/eje-08-0205
  91. Leonart, 2019, Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies, Endocrine, 63, 18, 10.1007/s12020-018-1729-7 · doi:10.1007/s12020-018-1729-7
  92. Buchfelder, 2018, Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in acrostudy, Eur J Endocrinol, 179, 419, 10.1530/EJE-18-0616 · doi:10.1530/eje-18-0616
  93. Brue, 2019, Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy, Endocrine, 63, 563, 10.1007/s12020-018-1792-0 · doi:10.1007/s12020-018-1792-0
  94. Moller, 2009, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects, Endocr Rev, 30, 152, 10.1210/er.2008-0027 · DOI · Paper page
  95. Gatto, 2025, Differential impact of medical therapies for acromegaly on glucose metabolism, Int J Mol Sci, 26, 465, 10.3390/ijms26020465 · DOI
  96. Barkan, 2005, Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant, J Clin Endocrinol Metab, 90, 5684, 10.1210/jc.2005-0331 · DOI · Paper page
  97. Salvatori, 2022, Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience, Pituitary, 25, 420, 10.1007/s11102-022-01206-2 · doi:10.1007/s11102-022-01206-2
  98. Dichtel, 2021, Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly, Clin Endocrinol (Oxf), 94, 58, 10.1111/cen.14309 · DOI
  99. Neggers, 2011, Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients, Pituitary, 14, 253, 10.1007/s11102-010-0289-5 · DOI
  100. Muhammad, 2016, What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?, Eur J Endocrinol, 174, 663, 10.1530/EJE-15-1150 · doi:10.1530/eje-15-1150
  101. Camara, 2019, Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study, Pituitary, 22, 137, 10.1007/s11102-019-00943-1 · DOI
  102. Feenstra, 2005, Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly, Lancet, 365, 1644, 10.1016/S0140-6736(05)63011-5 · DOI
  103. Trainer, 2009, A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly, Clin Endocrinol (Oxf), 71, 549, 10.1111/j.1365-2265.2009.03620.x · DOI
  104. Neggers, 2014, Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly, J Clin Endocrinol Metab, 99, 3644, 10.1210/jc.2014-2032 · doi:10.1210/jc.2014-2032
  105. Ma, 2020, Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies, BMC Endocr Disord, 20, 126, 10.1186/s12902-020-0545-2 · doi:10.1186/s12902-020-0545-2
  106. Jørgensen, 2005, Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist, J Clin Endocrinol Metab, 90, 5627, 10.1210/jc.2005-0531 · DOI · Paper page
  107. van der Lely, 2001, Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient, J Clin Endocrinol Metab, 86, 478, 10.1210/jcem.86.2.7206 · doi:10.1210/jcem.86.2.7206
  108. Leung, 2000, Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation, J Clin Endocrinol Metab, 85, 4712
  109. Neggers, 2008, Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant, J Clin Endocrinol Metab, 93, 3853, 10.1210/jc.2008-0669 · DOI · Paper page
  110. De Marinis, 2007, Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA, Pituitary, 10, 227, 10.1007/s11102-007-0037-7 · DOI
  111. Bonert, 2020, Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial, J Clin Endocrinol Metab, 105, e3236, 10.1210/clinem/dgaa444 · DOI
  112. Coopmans, 2019, The position of combined medical treatment in acromegaly, Arch Endocrinol Metab, 63, 646, 10.20945/2359-3997000000195 · DOI
  113. Chiloiro, 2019, Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study, J Clin Endocrinol Metab, 104, 5478, 10.1210/jc.2019-00825 · doi:10.1210/jc.2019-00825
  114. Chiloiro, 2021, Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response, Eur J Endocrinol, 184, 217, 10.1530/EJE-20-0767 · doi:10.1530/eje-20-0767
  115. Giraldi, 2020, The role of dopamine agonists in pituitary adenomas, Endocrinol Metab Clin North Am, 49, 453, 10.1016/j.ecl.2020.05.006 · DOI
  116. Shimon, 2024, Real-world value of cabergoline in the treatment of acromegaly, Best Pract Res Clin Endocrinol Metab, 38, 101887, 10.1016/j.beem.2024.101887 · DOI
  117. Higham, 2012, Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial, J Clin Endocrinol Metab, 97, 1187, 10.1210/jc.2011-2603 · DOI
  118. Sandret, 2011, Place of cabergoline in acromegaly: a meta-analysis, J Clin Endocrinol Metab, 96, 1327, 10.1210/jc.2010-2443 · DOI · Paper page
  119. Bernabeu, 2013, Pegvisomant and cabergoline combination therapy in acromegaly, Pituitary, 16, 101, 10.1007/s11102-012-0382-z · DOI
  120. Fleseriu, 2021, Addition of cabergoline to oral octreotide capsules may improve biochemical control in patients with acromegaly who are inadequately controlled with monotherapy, Endocr Abs, 73, PEP8.3
  121. Amodru, 2024, Changes in multi-modality management of acromegaly in a tertiary centre over 2 decades, Pituitary, 27, 294, 10.1007/s11102-024-01387-y · doi:10.1007/s11102-024-01387-y
  122. Maione, 2017, Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry, Eur J Endocrinol, 176, 645, 10.1530/EJE-16-1064 · DOI · Paper page
  123. Castinetti, 2010, Role of stereotactic radiosurgery in the management of pituitary adenomas, Nat Rev Endocrinol, 6, 214, 10.1038/nrendo.2010.4 · DOI
  124. Singh, 2020, Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes, J Neurooncol, 148, 401, 10.1007/s11060-020-03552-2 · DOI
  125. Ding, 2019, Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study, Neurosurgery, 84, 717, 10.1093/neuros/nyy178 · doi:10.1093/neuros/nyy178
  126. Cordeiro, 2019, Hypopituitarism after gamma knife radiosurgery for pituitary adenomas: a multicenter, international study, J Neurosurg, 131, 1188, 10.3171/2018.5.JNS18509 · DOI
  127. Hamblin, 2022, Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance, Lancet Diabetes Endocrinol, 10, 581, 10.1016/S2213-8587(22)00160-7 · DOI
  128. Castinetti, 2021, Lack of delayed neurocognitive side effects of gamma knife radiosurgery in acromegaly: the later-ac study, Eur J Endocrinol, 186, 37, 10.1530/EJE-21-0826 · doi:10.1530/eje-21-0826
  129. Mantziaris, 2025, Stereotactic radiosurgery and fractionated radiation therapy in the management of pituitary tumors, Neurooncol Adv, 7, i58
  130. Gonzales-Virla, 2019, Efficacy and safety of fractionated conformal radiation therapy in acromegaly: a long-term follow-up study, Endocrine, 65, 386, 10.1007/s12020-019-01955-4 · doi:10.1007/s12020-019-01955-4
  131. Petit, 2007, Proton stereotactic radiosurgery in management of persistent acromegaly, Endocr Pract, 13, 726, 10.4158/EP.13.7.726 · DOI

Metadata

Authors
Castinetti, F., & Ioachimescu, A. G.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2026-04-08
Volume
111
Issue
Supplement_1
Pages
S64-S76
ISSN
  • 0021-972X
  • 1945-7197
DOI
10.1210/clinem/dgag152
Cited by
3
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 1 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current treatment landscape of acromegaly. https://app.cochat.ai/papers/10.1210/clinem/dgag152
The paper
Castinetti, F., & Ioachimescu, A. G. (2026). Current treatment landscape of acromegaly. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag152

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.